Minimally invasive treatment of benign prostatic hyperplasia with high intensity focused ultrasound using the Sonablate™ system: An updated report of phase III clinical studies conducted in the USA

Thomas Gardner, Michael Koch, Arieh Shalhav, Richard Bihrle, Richard Foster, Christopher Steidle, Ivan Grunberger, Allen Seftel, Martin Resnick, James Cochran, Victor Rao, Narendra T. Sanghvi

Research output: Chapter in Book/Report/Conference proceedingConference contribution

5 Citations (Scopus)

Abstract

Phase III multicenter study was conducted in the USA under the FDA approved protocol, to establish the safety and efficacy of High Intensity Focused Ultrasound (HIFU) in the treatment of Benign Prostatic Hyperplasia (BPH) using the Sonablate™ system. A total of sixty eight patients have been treated to date in the Phase III study. Transrectal probes capable of real-time ultrasound imaging of the prostate and well as delivering the HIFU energy to the selected region in the prostate gland were used. Probes with different focal lengths were used to treat different size of prostate glands. The patients were treated in one treatment session and were followed up to a period of one year following the treatment. The subjects underwent physical exam, Digital Rectal Examination (DRE), cystoscopy, Transrectal Ultrasound (TRUS), blood work, urine exam and were given standard questionnaires before treatment and during the follow up period. Under this protocol HIFU was found to be safe and effective in reducing the BPH related symptoms and improving the peak urinary flow rate with preservation of sexual function and no permanent side effects.

Original languageEnglish
Title of host publicationProceedings of SPIE - The International Society for Optical Engineering
EditorsW.T.W. Riese, K.E. Bartels, L.S. Bass, K.W. Gregory
Pages107-114
Number of pages8
Volume4609
DOIs
StatePublished - 2002
EventLasers in Surgery: Advanced Characterization, Therapeutics, and Systems XII - San Jose, CA, United States
Duration: Jan 19 2002Jan 22 2002

Other

OtherLasers in Surgery: Advanced Characterization, Therapeutics, and Systems XII
CountryUnited States
CitySan Jose, CA
Period1/19/021/22/02

Fingerprint

Ultrasonics
prostate gland
urine
probes
blood
safety
flow velocity
examination
Blood
Flow rate
Imaging techniques
energy

Keywords

  • Benign Prostatic Hyperplasia
  • High Intensity Focused Ultrasound
  • Minimally invasive therapy
  • Prostate

ASJC Scopus subject areas

  • Electrical and Electronic Engineering
  • Condensed Matter Physics

Cite this

Gardner, T., Koch, M., Shalhav, A., Bihrle, R., Foster, R., Steidle, C., ... Sanghvi, N. T. (2002). Minimally invasive treatment of benign prostatic hyperplasia with high intensity focused ultrasound using the Sonablate™ system: An updated report of phase III clinical studies conducted in the USA. In W. T. W. Riese, K. E. Bartels, L. S. Bass, & K. W. Gregory (Eds.), Proceedings of SPIE - The International Society for Optical Engineering (Vol. 4609, pp. 107-114) https://doi.org/10.1117/12.432046

Minimally invasive treatment of benign prostatic hyperplasia with high intensity focused ultrasound using the Sonablate™ system : An updated report of phase III clinical studies conducted in the USA. / Gardner, Thomas; Koch, Michael; Shalhav, Arieh; Bihrle, Richard; Foster, Richard; Steidle, Christopher; Grunberger, Ivan; Seftel, Allen; Resnick, Martin; Cochran, James; Rao, Victor; Sanghvi, Narendra T.

Proceedings of SPIE - The International Society for Optical Engineering. ed. / W.T.W. Riese; K.E. Bartels; L.S. Bass; K.W. Gregory. Vol. 4609 2002. p. 107-114.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Gardner, T, Koch, M, Shalhav, A, Bihrle, R, Foster, R, Steidle, C, Grunberger, I, Seftel, A, Resnick, M, Cochran, J, Rao, V & Sanghvi, NT 2002, Minimally invasive treatment of benign prostatic hyperplasia with high intensity focused ultrasound using the Sonablate™ system: An updated report of phase III clinical studies conducted in the USA. in WTW Riese, KE Bartels, LS Bass & KW Gregory (eds), Proceedings of SPIE - The International Society for Optical Engineering. vol. 4609, pp. 107-114, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XII, San Jose, CA, United States, 1/19/02. https://doi.org/10.1117/12.432046
Gardner T, Koch M, Shalhav A, Bihrle R, Foster R, Steidle C et al. Minimally invasive treatment of benign prostatic hyperplasia with high intensity focused ultrasound using the Sonablate™ system: An updated report of phase III clinical studies conducted in the USA. In Riese WTW, Bartels KE, Bass LS, Gregory KW, editors, Proceedings of SPIE - The International Society for Optical Engineering. Vol. 4609. 2002. p. 107-114 https://doi.org/10.1117/12.432046
Gardner, Thomas ; Koch, Michael ; Shalhav, Arieh ; Bihrle, Richard ; Foster, Richard ; Steidle, Christopher ; Grunberger, Ivan ; Seftel, Allen ; Resnick, Martin ; Cochran, James ; Rao, Victor ; Sanghvi, Narendra T. / Minimally invasive treatment of benign prostatic hyperplasia with high intensity focused ultrasound using the Sonablate™ system : An updated report of phase III clinical studies conducted in the USA. Proceedings of SPIE - The International Society for Optical Engineering. editor / W.T.W. Riese ; K.E. Bartels ; L.S. Bass ; K.W. Gregory. Vol. 4609 2002. pp. 107-114
@inproceedings{89a9461db43a44dd9b6d7c82a7532570,
title = "Minimally invasive treatment of benign prostatic hyperplasia with high intensity focused ultrasound using the Sonablate™ system: An updated report of phase III clinical studies conducted in the USA",
abstract = "Phase III multicenter study was conducted in the USA under the FDA approved protocol, to establish the safety and efficacy of High Intensity Focused Ultrasound (HIFU) in the treatment of Benign Prostatic Hyperplasia (BPH) using the Sonablate™ system. A total of sixty eight patients have been treated to date in the Phase III study. Transrectal probes capable of real-time ultrasound imaging of the prostate and well as delivering the HIFU energy to the selected region in the prostate gland were used. Probes with different focal lengths were used to treat different size of prostate glands. The patients were treated in one treatment session and were followed up to a period of one year following the treatment. The subjects underwent physical exam, Digital Rectal Examination (DRE), cystoscopy, Transrectal Ultrasound (TRUS), blood work, urine exam and were given standard questionnaires before treatment and during the follow up period. Under this protocol HIFU was found to be safe and effective in reducing the BPH related symptoms and improving the peak urinary flow rate with preservation of sexual function and no permanent side effects.",
keywords = "Benign Prostatic Hyperplasia, High Intensity Focused Ultrasound, Minimally invasive therapy, Prostate",
author = "Thomas Gardner and Michael Koch and Arieh Shalhav and Richard Bihrle and Richard Foster and Christopher Steidle and Ivan Grunberger and Allen Seftel and Martin Resnick and James Cochran and Victor Rao and Sanghvi, {Narendra T.}",
year = "2002",
doi = "10.1117/12.432046",
language = "English",
volume = "4609",
pages = "107--114",
editor = "W.T.W. Riese and K.E. Bartels and L.S. Bass and K.W. Gregory",
booktitle = "Proceedings of SPIE - The International Society for Optical Engineering",

}

TY - GEN

T1 - Minimally invasive treatment of benign prostatic hyperplasia with high intensity focused ultrasound using the Sonablate™ system

T2 - An updated report of phase III clinical studies conducted in the USA

AU - Gardner, Thomas

AU - Koch, Michael

AU - Shalhav, Arieh

AU - Bihrle, Richard

AU - Foster, Richard

AU - Steidle, Christopher

AU - Grunberger, Ivan

AU - Seftel, Allen

AU - Resnick, Martin

AU - Cochran, James

AU - Rao, Victor

AU - Sanghvi, Narendra T.

PY - 2002

Y1 - 2002

N2 - Phase III multicenter study was conducted in the USA under the FDA approved protocol, to establish the safety and efficacy of High Intensity Focused Ultrasound (HIFU) in the treatment of Benign Prostatic Hyperplasia (BPH) using the Sonablate™ system. A total of sixty eight patients have been treated to date in the Phase III study. Transrectal probes capable of real-time ultrasound imaging of the prostate and well as delivering the HIFU energy to the selected region in the prostate gland were used. Probes with different focal lengths were used to treat different size of prostate glands. The patients were treated in one treatment session and were followed up to a period of one year following the treatment. The subjects underwent physical exam, Digital Rectal Examination (DRE), cystoscopy, Transrectal Ultrasound (TRUS), blood work, urine exam and were given standard questionnaires before treatment and during the follow up period. Under this protocol HIFU was found to be safe and effective in reducing the BPH related symptoms and improving the peak urinary flow rate with preservation of sexual function and no permanent side effects.

AB - Phase III multicenter study was conducted in the USA under the FDA approved protocol, to establish the safety and efficacy of High Intensity Focused Ultrasound (HIFU) in the treatment of Benign Prostatic Hyperplasia (BPH) using the Sonablate™ system. A total of sixty eight patients have been treated to date in the Phase III study. Transrectal probes capable of real-time ultrasound imaging of the prostate and well as delivering the HIFU energy to the selected region in the prostate gland were used. Probes with different focal lengths were used to treat different size of prostate glands. The patients were treated in one treatment session and were followed up to a period of one year following the treatment. The subjects underwent physical exam, Digital Rectal Examination (DRE), cystoscopy, Transrectal Ultrasound (TRUS), blood work, urine exam and were given standard questionnaires before treatment and during the follow up period. Under this protocol HIFU was found to be safe and effective in reducing the BPH related symptoms and improving the peak urinary flow rate with preservation of sexual function and no permanent side effects.

KW - Benign Prostatic Hyperplasia

KW - High Intensity Focused Ultrasound

KW - Minimally invasive therapy

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=18644380135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18644380135&partnerID=8YFLogxK

U2 - 10.1117/12.432046

DO - 10.1117/12.432046

M3 - Conference contribution

AN - SCOPUS:18644380135

VL - 4609

SP - 107

EP - 114

BT - Proceedings of SPIE - The International Society for Optical Engineering

A2 - Riese, W.T.W.

A2 - Bartels, K.E.

A2 - Bass, L.S.

A2 - Gregory, K.W.

ER -